Navigation Links
Mylan Launches Generic Lipitor® in Five European Countries
Date:5/11/2012

PITTSBURGH and LYON, France, May 11, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Atorvastatin Calcium Tablets, 10 mg, 20 mg, 40 mg and 80 mg in France, Belgium, the UK, the Netherlands and Ireland. Mylan has received marketing authorization from each country's respective health authority to begin selling its product immediately. Atorvastatin Calcium is the generic version of Pfizer's Lipitor® Tablets. This product is indicated for the prevention of cardiovascular disease and hypercholesterolemia.

Mylan CEO Heather Bresch said: "We are pleased to provide access to generic Lipitor to more than 4 million patients in five countries across Europe. Mylan is committed to expanding access to high quality medicine in Europe and around the world. Mylan's launch of Atorvastatin Calcium Tablets will help to provide health care systems in these markets with an estimated $700 million (euro 500 million) of savings in 2012 associated with the generic availability of this important medicine."

In France, Belgium, the UK, the Netherlands and Ireland, Lipitor had total sales of $1.6 billion (euro 1.126 billion) for the twelve months ending Dec. 31, 2011, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
2. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement with Teva
3. Mylan Launches Generic Version of Zyprexa® Tablets
4. Mylan Launches First Generic Version of Lescol® Capsules
5. Mylan Schedules First Quarter 2012 Financial Results Conference Call and Live Webcast
6. Mylan One of First to Launch Generic Version of Boniva®
7. Mylan Canada Receives Health Canada Approval for Generic Version of Crestor®
8. Mylan Continues to Pursue Damages and Injunction Against Sunovions Brovana® in Ongoing Litigation
9. Mylan Pharmaceuticals President Tony Mauro Elected Chairman of GPhA
10. Mylan Secures an Additional $300 Million of Committed Financing
11. Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2017)... ORLANDO, Fla. , Feb. 18, 2017 /PRNewswire/ ... announced that positive Phase 1 clinical data for Nektar,s ... carcinoma (RCC) were presented at ASCO GU 2017.  NKTR-214 ... cancer-fighting T cells and Natural Killer (NK) cell abundance ... PD-1 on these immune cells.  The results were presented ...
(Date:2/17/2017)... Feb. 17, 2017  Ethicon, Inc. today announced ... a privately held medical device company that manufactures ... System, a novel minimally invasive device for the ... Medical will enable Ethicon to offer patients a ... Nissen fundoplication surgical procedure. 1 ...
(Date:2/17/2017)... and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing ... ... the US, Canada , Japan , ... of World. Annual estimates and forecasts are provided for the period 2015 ... Market data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology:
(Date:2/18/2017)... , ... February 18, 2017 , ... ... provides the latest information and contact points to easily connect elderly veterans of ... assisted living, and elder-care funding. It also conveys material on this year's increase ...
(Date:2/17/2017)... ... 17, 2017 , ... For the first time, International Scholarship ... exhibit floor for the 2017 HIMSS Conference & Exhibition at the ... more than 40,000 healthcare industry professionals are expected at the conference, where they ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth ... most widely used electronic patient signatures solution in healthcare . , Since ...
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... premier sponsor and exhibitor at Molecular Medicine Tri-Conference February 20 – 22 in ... Wednesday, Inspirata will showcase its anatomic and molecular pathology workflow solution, as well ...
(Date:2/16/2017)... York, New York (PRWEB) , ... February 17, ... ... work and determination. After what took over 10 years of research, development and ... technology, NTX Technology™. NTX Technology™ is a patented compound of FDA approved ingredients ...
Breaking Medicine News(10 mins):